Association of GOLPH2 expression with survival in non-small-cell lung cancer: clinical implications and biological validation

Biomark Med. 2017 Nov;11(11):967-977. doi: 10.2217/bmm-2017-0199. Epub 2017 Sep 7.

Abstract

Aim: We investigated the role of GOLPH2 in non-small-cell lung cancer (NSCLC).

Methods: We analyzed the relationship between the expression of GOLPH2 and the clinical pathological characteristics of patients with NSCLC. The function of GOLPH2 in NSCLC cell lines was also explored through overexpression and knockdown studies.

Results: The positive expression rate of GOLPH2 protein in NSCLC tissue was higher than that of normal lung tissue. We found that positive GOLPH2 expression was closely associated with unfavorable features of patients with NSCLC. The GOLPH2 expression was an independent predictor of the prognosis of patients with NSCLC. That GOLPH2 can promote the proliferation and invasion of NSCLC cells.

Conclusion: The GOLPH2 is a novel marker for NSCLC.

Keywords: GOLPH2; NSCLC; invasion; prognosis; proliferation.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / biosynthesis*
  • Cancer Survivors
  • Carcinoma, Non-Small-Cell Lung / metabolism*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / mortality
  • Male
  • Membrane Proteins / biosynthesis*
  • Middle Aged
  • Neoplasm Proteins / biosynthesis*

Substances

  • Biomarkers, Tumor
  • GOLM1 protein, human
  • Membrane Proteins
  • Neoplasm Proteins